Recruiting
PirtobrUtinib as frontline Therapy for elderly unfit/frail patient with MAntle cell lymphoma: a phase II study of the Fondazione Italiana Linfomi (FIL)
2025-521666-10-01· Phase 2· Fondazione Italiana Linfomi Ets· Source
Not yet recruiting
A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36
2025-522084-15-00· Phase 2/3· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source
Not yet recruiting
Hyperprogression upon cemiplimab alone or with chemotherapy in PD-L1 ≥ 50% NSCLC: a biomarker guided phase 2 trial – HYPERBOLIC study
2025-521583-35-00· Phase 2· Universita' Vita-salute S. Raffaele· Source
Recruiting
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
NCT07058077· Phase 2/3· Merck Sharp & Dohme LLC· Source
Recruiting
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827· Phase 3· Takeda· Source
Recruiting
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
NCT06486883· Phase 2· MedSIR· Source
Recruiting
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
NCT06409936· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357· Phase 3· Biogen· Source
Recruiting
Clinical trial with a combination of Rituximab and Golcadomide as first line therapy for older frail patients with Diffuse Large B-cells non-Hodgkin Lymphoma
2023-506206-38-00· Phase 2· Fondazione Italiana Linfomi Ets· Source
Recruiting
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
NCT06713837· Phase 3· Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS· Source
Active, not recruiting
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT06608927· Phase 3· Arcus Biosciences, Inc.· Source
Recruiting
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
NCT06382948· Phase 3· MedSIR· Source
Recruiting
PHASE III RANDOMIZED STUDY OF FOLFOXIRI PLUS BEVACIZUMAB AND ATEZOLIZUMAB VERSUS FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF UNRESECTABLE pMMR AND IMMUNOSCORE IC-HIGH METASTATIC COLORECTAL CANCER PATIENTS. The AtezoTRIBE2 Study
2023-506632-32-00· Phase 3· Fondazione GONO G.I.· Source
Active, not recruiting
Clinical trial with Mosunetuzumab and Zanubrutinib in patients with relapsed/refractory follicular lymphoma
2023-506049-52-00· Phase 2· Fondazione Italiana Linfomi Ets· Source
Active, not recruiting
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
NCT06161441· Phase 2· Regeneron Pharmaceuticals· Source
Active, not recruiting
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376· Phase 3· Alexion Pharmaceuticals, Inc.· Source
Recruiting
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566· Phase 3· Ascentage Pharma Group Inc.· Source
Active, not recruiting
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773· Phase 3· Taiho Oncology, Inc.· Source
Recruiting
Phase III trial comparing local radiotherapy alone or with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial.
2022-502775-29-01· Phase 3· Fondazione Italiana Linfomi Onlus· Source
Active, not recruiting
Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL
NCT05478512· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source
Recruiting
Venetoclax in combination with Ibrutinib and Rituximab or conventional
chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients
with Mantle Cell Lymphoma.
2022-501808-96-00· Phase 2· Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR· Source
Active, not recruiting
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778· Phase 3· AbbVie· Source
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020· Phase 3· Pfizer· Source
Active, not recruiting
Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients
NCT05306301· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source
Recruiting
Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab
NCT05568212· Phase 2· Fondazione Ricerca Traslazionale· Source
Active, not recruiting
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma
NCT05058404· Phase 3· Fondazione Italiana Linfomi - ETS· Source
Active, not recruiting
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
NCT04722848· Phase 3· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source
Active, not recruiting
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052· Phase 3· Incyte Corporation· Source
Recruiting
Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)
NCT04184505· Phase 3· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source
Recruiting
Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
NCT04168502· Phase 3· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source
Recruiting
Study to identify the most appropriate therapy for patients with Acute Myeloid Leukemia carrying FLT3 mutation, using the PBC biomarker to customize therapy.
NCT04174612· Phase 3· Fondazione G.I.M.Em.A Franco Mandelli Ets· Source
Recruiting
A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR mutations
NCT04811001· Phase 2· Fondazione Ricerca Traslazionale· Source
Recruiting
Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-small-cell lung cancer patients
2024-517200-10-00· Phase 2· Fondazione Ricerca Traslazionale· Source
Active, not recruiting
Phase II multicenter single arm study to evaluate the efficacy and safety of ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance in untreated patients with Activated-B-Cell (ABC)-DLBCL at intermediate-high and high risk (IPI ≥2)
NCT03731234· Phase 2· Fondazione Italiana Linfomi Ets· Source
Recruiting
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
NCT03968393· Phase 4· Population Health Research Institute· Source
Active, not recruiting
MILES5 – A randomized phase 2 study comparing immunotherapy with chemotherapy in the treatment of elderly patients with advanced NSCLC
NCT03975114· Phase 2· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source
Active, not recruiting
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients
NCT02390869· Phase 3· Fondazione Italiana Linfomi - ETS· Source